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ABSTRACT
Vascular calcification involves passive degeneration and an active process of arterial mineralisation, 
resembling osteogenesis. In chronic kidney disease, several proteins that physiologically control bone 
mineralisation, are also involved in the molecular and cellular mechanisms of the pathogenesis of vascular 
calcification. In fact, arterial cells grown in culture are induced to become osteogenic by inflammatory and 
atherogenic stimuli, such as high phosphate concentration. Mechanisms linking them must be considered in 
clinical decisions. Further understanding of processes causing vascular calcification may be considered for 
new therapeutic options for vascular disease in renal patients.
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INTRODUCTION
Patients with chronic kidney disease (CKD) develop 
vascular calcification (VC) much faster than the 
general population.1 In particular, it has been widely 
demonstrated how CKD represents an independent 
risk factor of cardiovascular mortality and all-
cause mortality. Vascular calcifications are not only 
the result of the mere passive process of crystal 
deposition, but also an actively regulated process 
that develops in response to physiological and 
pathological conditions.2 Several risk factors play a 
key role in this rapid vascular ageing. They are divided 
into “classic” risk factors such as age, gender, dialysis 
vintage, inflammatory status, calcium-phosphate 
disorders, and diabetes,3 and new “non-classic” 
risk factors such as bone-related proteins: fetuin-A 
(2-Heremans-Schmid glycoprotein, AHSG), matrix-
carboxyglutamic acid protein (MGP), pyrophosphate, 
osteoprotegerin (OPG), and bone morphogenetic 
protein-2 (BMP-2). (Table 1) In addition, CKD 
promotes atherosclerosis.6 In fact; the reduction 
of renal function promotes the development of an 
inflammatory status (increased levels of C-reactive 
protein) and lipid abnormalities that contribute to 
INHIBITORS PROMOTERS
Fetuin-A 
(2-Heremans-Schmid 
glycoprotein, AHSG)
OPG 
(Osteoprotegerin)
MGP (Matrix-GLA-
Protein)
BMP 2/4 (Bone 
Morphogenic Protein 
2/4)
Pyrophosphate
Table 1. Inhibitors and promoters of vascular 
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endothelial dysfunction and vascular calcification. 
The prevalence and progression of vascular 
calcification increases dramatically once patients 
are on dialysis,4 and the vascular phenotype of 
even young dialysis patients can be compared with 
that of octogenarians.5 Vascular calcification starts 
developing in the early stages of CKD (stage III 25%, 
stage IV 35%) and is present in over 50% of patients 
at the time of dialysis.
PATHOPHYSIOLOGY
Ectopic vascular calcifications follow a very 
similar developing process to physiological bone 
formation. At sites of calcification, there is an up-
regulated expression of mineralisation proteins, 
normally confined to bone and cartilage; this 
event induces osteo-chondrocyte-like changes 
in vascular smooth muscle cells (VSMCs).7 These 
proteins include a number of transcription factors, 
such as Runx2 (Cbfa-1), Osterix, Msx2, and Sox9.8,9 
To create a microenvironment that is permissive for 
calcification,  specialised membrane-bound bodies 
called matrix vesicles, serve as nucleation sites for 
hydroxyapatite.9,10 VSMC-derived vesicles do not 
calcify until calcification inhibitors, such as Fetuin-A 
and MGP, are maintained in normal ranges. When 
calcification inhibitor levels are low, VSMCs produce 
mineralisation-competent vesicles that contain 
preformed hydroxyapatite. 10,11
HIGH PHOSPHATE AND VASCULAR 
CALCIFICATION
Phosphate (P) homeostasis in normal subjects is 
regulated by intestinal absorption, renal excretion, 
and bone resorption. However, in subjects with 
CKD, P renal excretion is reduced. Nevertheless, 
P levels are maintained among normal limits by 
reducing P tubular resorption through increasing 
parathyroid hormone (PTH) and fibroblast growth 
factor 23 (FGF23). In the same setting, reduction 
of intestinal phosphorous absorption happens due 
to the reduction of plasma levels of calcitriol.12 At 
stages IV and V of CKD, dietary intake of P tends 
to exceed renal excretion capacity, resulting in 
hyperphosphataemia.  Abnormalities in mineral 
metabolism have been claimed to be a causal factor 
for  the  development  of  vascular  calcification  in                                               
CKD patients.
Several studies have shown that high phosphorus 
levels stimulate the development of VC in an in vitro 
model of VSMCs.13 In vitro studies have demonstrated 
that high phosphate concentration is responsible for 
VC formation through a specific activation of the 
core-binding factor alpha-1 (Cbfa-1), an osteoblast-
specific gene that regulates the expression of 
several bone morphogenetic proteins.14 In CKD, the 
expression of these proteins was also stimulated 
by uraemic patients’ serum with normal serum 
phosphate, suggesting that uraemic milieu also has 
a role in CV pathogenesis.15 Interestingly, calcified 
arteries from CKD patients showed an increased 
expression of both Cbfa-1 and osteopontin.16 These 
data suggest that VC is an active process due, 
not only to calcium-phosphate salt deposition in 
artery wall, but also to a genomic regulation driven 
by uraemic environment and elevations in serum 
phosphate levels. 
FETUIN – A
Human fetuin-A (AHSG, alpha2-Heremans Schmid 
glycoprotein, alpha2HS-glycoprotein, alpha2-
HSG) is an extracellular calcium-regulatory protein 
acting as a potent inhibitor of calcium phosphate 
precipitation. It is a member of a family of four 
structurally-related plasma proteins containing 
cystatin-like protein domains. The cystatin family 
harbours type 1 (mainly intracellular proteins), type 2 
(mainly extracellular proteins), and type 3 cystatins 
(plasma proteins). Cystatin domain 1 in fetuin-A is 
strongly negatively charged with a high affinity for 
calcium-rich minerals.17
Fetuin-A is one of the non-collagenous, most 
abundant proteins in bone, accounting for 25% 
non-collagenous proteins. Serum fetuin-A has an 
anti-inflammatory property; the demonstration that 
this protein specifically prevents neutrophils from 
activation by hydroxyapatite crystals, supports 
this issue.18 Furthermore, anti-apoptotic activity of 
fetuin-A has been observed in smooth muscle cells.19 
Beside these findings, fetuin-A showed an important 
role in the mineralisation process. 
Fetuin-A is responsible for mineral accumulation in 
bone from plasma, thanks to its high affinity for bone 
minerals, especially for nascent apatite mineral. 
For this reason, it is an inhibitor of de novo apatite 
formation from supersaturated mineral solutions, 
but it does not dissolve preformed minerals.20 
Specifically, fetuin-A binds calcium phosphate and 
calcium carbonate with high affinity.  Haemodialysis 
patients with low serum AHSG levels have a major 
risk of CV and all-cause mortality.21 This observation 
by Ketteler et al.21 suggests that AHSG may be 
involved in preventing the accelerated extraskeletal 
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population of 115 haemodialysis patients supports 
this hypothesis, as VC was associated not only with 
increasing age and a history of cardiovascular events, 
but also with abnormal values of inflammatory 
markers, such as reduction in AHSG and albumin and 
an increase in C-reactive protein and fibrinogen.22
MATRIX GLA PROTEIN 
Extracellular matrix GLA protein (MGP) is a member 
of the vitamin-K-dependent protein family, and it is 
a calcification inhibitor found in vascular and other 
soft tissue.23,24 MGP promotes VSMC differentiation, 
antagonises BMP (BMP2 and BMP4) signalling and 
prevents osteochondrogenic lineage reprogramming 
of VSMCs. In mice, targeted deletion of the 
MGP gene results in rapid and complete arterial 
calcification, resulting in death by 6 weeks.25 MGP 
is synthesised in the uncarboxylated form (ucMGP) 
and performs its action after vitamin K-dependent 
carboxylation. Without sufficient vitamin K, it 
remains decarboxylated and does not inhibit 
calcification.26,27 The degree of γ-carboxylation 
required for MGP to inhibit calcification in humans 
is not known. Decarboxylated MGP form seems 
to be in high concentrations in calcified vessels, 
while carboxylated MGP form is more abundant in 
healthy vascular tissue.28 This demonstrates that 
lack of functional MGP increases risk for vascular 
calcification. In addition to being carboxylated, MGP 
needs a post-translational phosphorylation, which is 
also thought to contribute to its functionality.29 The 
phosphorylated ucMGP accumulates in a detectable 
amount in plasma.30 
The role of MGP in vascular calcification has been 
elucidated in animal models, whereas in humans, 
data are conflicting. It has been suggested that the 
amount of ucMGP in the circulation is increased 
among patient populations characterised by 
pathologic soft-tissue calcification.29-31 The studies 
that examined the association between plasma 
ucMGP and vascular calcification are limited to 
case-control comparisons or specific disease 
populations.29-31 To evaluate the utility of ucMGP as 
a predictive marker of coronary artery calcification 
(CAC), it is necessary to examine a population free 
of clinical events. 
In a randomised controlled trial with vitamin K 
supplementation, Shea et al.32 found that older 
community-dwelling adults who adhered to 
phylloquinone (vitamin K1) supplementation showed 
less CAC progression over 3 years. The impact of MGP 
on regulation of calcification in humans appears to 
have a genetic component. An association between 
polymorphisms of the MGP gene and myocardial 
infarction has been described in low-risk individuals.33 
Furthermore, their distribution has proved to differ 
significantly in CKD/haemodialysis patients as 
compared to healthy controls, and particular alleles 
are associated with an increase in cardiovascular 
events in haemodialysis patients.34 Potentially, the 
identification of polymorphisms of the MGP gene, 
and their association with cardiovascular morbidity, 
is a critical step towards the understanding of 
the pathogenetic mechanisms of VC in CKD and           
dialysis patients.
PYROPHOSPHATE
Isopentenyl Pyrophosphate (IPP), a well-known 
inhibitor of hydroxyapatite formation in urine 
produced by VSMCs, chondrocytes and osteoblasts, 
is an important inhibitor of vascular calcifications. 
Its reactive chemical nature suggests that it is a 
compound used to bind or deliver oxygen and 
phosphate at tissue level for rapid employment. 
Several intracellular enzymatic reactions are 
responsible for its production.35 Plasma IPP is 
normally cleared by the kidney,36 however, serum 
IPP levels in haemodialysis patients are reduced.37 
Furthermore, the calcification-inhibitory action 
of IPP in vivo is well-documented. However, its 
simple chemical composition and heterogeneous 
metabolism, as well as the local nature of its action, 
hinder the development of a preparation for the 
clinical setting.
OSTEOPROTEGERIN
Osteoprotegerin (OPG) belongs to the tumour 
necrosis factor receptor superfamily. It acts as a 
soluble decoy receptor for the receptor activator 
of nuclear factor-kappa B Ligand (RANKL), lying 
on osteoclast membrane, and inhibits its interaction 
with membrane-bound receptor RANK. Through 
this mechanism, OPG is able to inhibit osteoclasts 
differentiation. RANKL/OPG/RANK axis is not only 
involved in regulation of bone-remodelling,38,39 but 
recent findings supported its role in carcinogenesis 
as well as central thermoregulation.40,41
This system has also been linked to the development 
of atherosclerosis and plaque destabilisation.42,43 
In observational studies, elevated circulating OPG 
levels have been associated with prevalence and 
severity of coronary artery disease, cerebrovascular 
disease, and peripheral vascular disease. Elevated 
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of coronary calcification in the general population 
as a marker of coronary atherosclerosis.44 OPG is 
produced by osteoblasts but also by many different 
tissues and cell types, including the lung, kidney, 
intestine and endothelial cells. Its biological effects 
are still not completely understood, but it seems to 
be involved in apoptosis.45
In renal patients, increased levels have been 
associated with abnormal aortic calcifications in 
patients on dialysis46 and with coronary artery 
calcifications in both dialysis and transplantation 
patients.47 There is an association of serum 
OPG levels with all-cause and cardiovascular 
mortality, both in patients on dialysis48  and  in                                                                          
transplantation patients.49
BONE MORPHOGENIC PROTEINS 
Bone morphogenic proteins (BMP) are secreted 
polypeptides, a subgroup of the transforming growth 
factor-beta (TGF-ß) superfamily of growth factors. 
BMPs were first identified in demineralised and 
pulverised bone powder capable of inducing ectopic 
endochondral bone formation in muscle.26 Over the 
years, more than 15 distinct BMP family members 
have been identified. In 1993, Bostrom, Demer and 
colleagues first demonstrated the expression of 
BMP2 in calcified human atherosclerotic plaques, 
and the capacity of BMPs to direct osteogenic 
programming of vascular mesenchymal progenitors 
of the pericyte lineage. When BMP2, BMP4, and BMP6, 
were detected in calcified areas of atherosclerotic 
lesions,50-52  it was therefore presumed that they 
enhanced vascular calcification, even more so when 
it became evident that vascular calcification is largely 
driven by osteogenesis in the vascular media.53,54 
However, BMP signalling is not only driving ectopic 
calcification but is also essential for cardiovascular 
development, with critical roles in the establishment 
of endothelial cells during vasculogenesis, the 
recruitment and differentiation of VSMC precursor 
cells, and vascular patterning.55,56 BMP activity is 
important for the regulation of phenotypic plasticity, 
proliferation, and differentiation in VSMC.52 BMP2 
in particular has an inhibitory effect on VSMC 
proliferation and differentiation, whereas BMP7 
promotes the VSMC phenotype transformation.54 
Furthermore, BMP inhibition, potentially in later 
steps, appears to be a key actor in maintaining VSMC 
differentiation. Many are the causes that promote 
increased levels of BMP. Among these, endothelial 
activation in response to pathogenic stimuli, such as 
inflammatory cytokines and shear stress, appear to 
play a key role in regulating serum levels of BMP.57,58
CONCLUSIONS
The astonishing mortality rate due to cardiovascular 
events in CKD has led to a great effort to identify 
causes and new potential strategies to improve 
survival in CKD. It seems that bone mineral 
abnormalities play a major role in inducing and 
sustaining cardiovascular damage in CKD. Improving 
understanding of cellular and molecular mechanisms 
of vascular calcification in CKD will give major tools 
to the clinicians to evaluate and choose treatments.
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